alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)
July 2006
A recent analysis is alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab).
These TNF inhibitors are wonder drugs for many patients with rheumatoid arthritis, Crohn's, and other autoimmune diseases.
But there's concern about an increased risk of serious infections and malignancies. Tumour necrosis factor plays a role in fighting infections and killing tumour cells.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive